University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
NCT Number: NCT06735924
This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Birmingham, Alabama, 35294, United States
Urinary oxalate excretion is derived from both dietary sources and endogenous synthesis. This study will use a low-oxalate controlled diet, repeat fasted urine collections and 24-hr urine collections on a low-oxalate diet, to determine the daily rate of endogenous oxalate synthesis in individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ingestion of a low-oxalate (< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
Time frame: 1 day
Average fasted hourly urinary oxalate excretion rate normalized to urinary creatinine excretion (mg oxalate / g urinary creatinine)
Time frame: 2 days
average urinary oxalate excretion rate normalized to urinary creatinine after equilibration on a low-oxalate fixed diet (mg urinary oxalate / g urinary creatinine)
University of Alabama at Birmingham
Other
Non Alcoholic Fatty Liver Disease and Endogenous Oxalate Synthesis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06138821
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT06986447
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Chandler, Arizona, United States
View Trial DetailsNCT07093346
Digestive System Diseases, Fatty Liver
Nottingham, United Kingdom
View Trial DetailsNCT07024212
Digestive System Diseases, Fatty Liver
Hangzhou, Zhejiang, China
View Trial Details